Life Science Investing Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
Knight Therapeutics Announces Exclusive License Agreement with AstraZeneca for Movantik/Moventig(R) in Canada and Israel
RecycLiCo’s U.S. Subsidiary and Alaska Energy Metals Corporation Enter Memorandum of Understanding to Advance Goal of Creating Domestic Critical Metal Supply Chain